Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Pfizer (PFE)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for PFE as compared to
Top Competitors
Drug Manufacturers - Major
Drug Manufacturers
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS (
See all
)
Revenue
►
45.8B
HIGH
R&D Expense
►
7.95B
AVG
R&D/Sales Ratio
►
16.5%
AVG
Number of Drugs
►
34.0
LOW
Number of Drug Approvals
►
2.00
AVG
Drug Applications
►
8.00
AVG
Number of Drugs in Phase I
►
26.0
AVG
Revenue
Number of Drugs
New Drug Applications
Number of Drug Approvals
Number of Drugs in Phase I
Number of Drugs in Phase II
R&D/Sales Ratio
Research and Development Expense
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
45.8B
HIGH
EBITDA
►
16.9B
AVG
Net Income
►
8.13B
AVG
Revenue Growth
►
-6.1%
AVG
Net Income Growth
►
-23%
AVG
Operating Margin
►
31.8%
AVG
Net Margin
►
17.7%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
1.14
AVG
Current Ratio
►
3.08
AVG
Quick Ratio
►
2.86
AVG
Interest Coverage Ratio
►
23.2
AVG
Book Value Per Share
►
8.26
Cash Per Share
►
0.529
Loading...
STOCK SUMMARY
Open
18.15
Day Range
18.12
-
18.48
52 Week Range
11.62
-
18.48
Volume
61.0M
Avg Volume (3 mo)
52.2M
Shares Outstanding
8.07B
Market Cap
148B
VALUATION
Price to Earnings (P/E)
►
17.4
AVG
Price to Book (P/B)
►
2.13
AVG
Price to Sales (P/S)
►
3.07
AVG
Return on Assets (ROA)
►
6.7%
AVG
Return on Equity (ROE)
►
12.2%
AVG
EV/EBITDA
►
10.9
AVG
Dividend Yield
3.6%
HIGH
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
-1.2%
Net Insider Buying 1yr
-1.6%
Held by insiders
0.1%
Held by institutions
44.4%